MANGOCEUTICALS, INC. (MGRX): Nasdaq/NYSE listing notice — Mangoceuticals (MGRX) gets Nasdaq notice for equity of $1.35M vs $2.5M minimum

MANGOCEUTICALS, INC.

Stockholders' equity of $1,354,821 as of Sep 30, 2023, below Nasdaq's $2.5M continued listing requirement.
Must submit a compliance plan by Dec 18, 2023; Nasdaq may grant up to 180-day extension if plan accepted.
Company also not in compliance with minimum bid price of $1.00 per share, previously reported.
Failure to regain compliance could result in delisting; management is evaluating options to address the deficiency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. In the Company’s Form 10-Q, the Company reported stockholders’ equity of $1,354,821, which is below the minimum stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). Additionally, as of the date of this Report, the Company

View on SEC.gov

Browse all listing & compliance notices →

MANGOCEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-039745

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.